Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV?

Clinical Infectious Diseases

Volumn 54, Issue 7, 2012, Pages 984-994

  Justice, Amy C ^a,b   Freiberg, Matthew S ^c,d   Tracy, Russ ^e   Kuller, Lew ^d   Tate, Janet P ^a,b   Goetz, Matthew Bidwell ^f,g   Fiellin, David A ^b   Vanasse, Gary J ^h   Butt, Adeel A ^c   Rodriguez Barradas, Maria C ⁱ   Gibert, Cynthia ^j,k   Oursler, Kris Ann ^l,m   Deeks, Steven G ⁿ   Bryant, Kendall ^o  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^l Medicine and Research Services   (United States)

^m UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; D DIMER; HEMOGLOBIN; INTERLEUKIN 6; VIRUS RNA;

ADULT; AGED; AGING; ARTICLE; BLOOD CLOTTING; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA COLLECTION METHOD; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORTALITY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIGENS, CD14; BIOLOGICAL MARKERS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84858132523     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir989     Document Type: Article

References (34)

1. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7:69-76.
2. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of "non-HIV" biomarkers. HIV Med 2009; 11:143-51.
3. Brown ST, Kyriakides K, kirkwood K, et al. The VACS risk index responds to treatment interventions and is highly correlated with and predictive of mortality events in the OPTIMA study. Int AIDS Conf 2010.
4. Akgun KM, Pisani MA, Fried TR, et al. Risk factors for medical intensive care unit admission in HIV infected veterans. Am Throacic Soc 2010.
5. Tate JP, Justice AC, Hughes MD, et al. Performance of the refined VACS risk index during the first 12 months of antiretroviral therapy among US and European subjects. In: Program and abstracts of the 15th International Workshop on HIV Observational Databases (Prague, Czech Republic). Bordeaux, France: IWHOD, 2011.
6. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
7. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
8. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
9. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
10. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71. (Pubitemid 44924494)
11. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44(8 Suppl 2):S13-24. (Pubitemid 44284253)
12. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the national VA health information system. Med Care 2006; 44(8 Suppl 2):S25-30. (Pubitemid 44284254)
13. D'Arminio MA, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-23. (Pubitemid 40280197)
14. Mocroft A, Sterne JA, Egger M, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48:1138-51.
15. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150:795-802.
16. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115:928-35. (Pubitemid 46294733)
17. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.
18. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.
19. Centers for Disease Control and Prevention. HIV/AIDS surveillance reports 2007. Department of Health and Human Services, 2009. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/index.htm. Accessed 10 June 2011.
20. Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med 2006; 14:159-63.
21. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003; 23:15-39. (Pubitemid 36268302)
22. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008; 13:959-67.
23. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Synd 2002; 29:54-7. (Pubitemid 34094307)
24. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44:463-9. (Pubitemid 46555383)
25. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24:5005-9. (Pubitemid 46631403)
26. Piasecki BA, Lewis JD, Reddy KR, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004; 40:892-9. (Pubitemid 39288122)
27. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-41. (Pubitemid 44232373)
28. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25. (Pubitemid 43980111)
29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-6. (Pubitemid 47171918)
30. Ravasi G, Lauriola M, Tinelli C, Brandolini M, Uglietti A, Maserati R. Comparison of glomerular filtration rate estimates vs. 24-h creatinine clearance in HIV-positive patients. HIV Med 2009; 10:219-28.
31. Barraclough K, Er L, Ng F, Harris M, Montaner J, Levin A. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract 2009; 111:c39-48.
32. Justice AC, Freiberg MS, Tracy R, et al. Biomarkers of inflammation, coagulation and monocyte activation are strongly associated with the VACS index among veterans on cART. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts. Alexandria, VA: CROI, 2011.
33. Tate JP, Justice AC. for the VACS Project Team. Change in a prognostic index for survival in HIV infection after one year on cART by level of adherence. In: Program and abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America, Vancouver, BC, Canada. Arlington, VA: IDSA, 2010.
34. Tate J, Justice AC, Hughes M, et al. An internationally validated mortality risk index for HIV infected individuals on antiretroviral therapy: performance by region, gender, risk group, and level of viral suppression. 2011.